Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD) - LARVOL DELTA

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination. (clinicaltrials.gov) - P4 | N=300 | Not yet recruiting | Sponsor: Best Healthcare Inc.

New P4 trial • Hepatology • Infectious Disease • Inflammation

Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study. (PubMed, Emerg Microbes Infect) - "PLWH included in the study received either Havrix or Vaqta. The seroprotection against HAV remained high in the long-term follow-up among PLWH on antiretroviral therapy after 2-dose HAV vaccination. Regular monitoring of seroresponses and timely administration of HAV vaccines are warranted to maintain seroprotection."

Journal • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

"Yikes. Our vaqta boxes don't come with needles, just the prefilled syringe" (@sweatPANCE4life)

Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults. (PubMed, Vaccine) - "Inactivated aluminum-adsorbed hepatitis A vaccines such as Havrix, Vaqta, and Avaxim are commonly used worldwide. Registered 03 April 2014. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000015906."

Journal • Hepatology • Infectious Disease • Inflammation

SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - P1 | N=54 | Active, not recruiting | Sponsor: Stanford University | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Hepatology • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients (clinicaltrials.gov) - P4 | N=153 | Completed | Sponsor: National Taiwan University Hospital | Recruiting ➔ Completed | Trial completion date: Sep 2022 ➔ Dec 2022 | Trial primary completion date: Sep 2021 ➔ Dec 2022

Trial completion • Trial completion date • Trial primary completion date • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation